🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

8 recruiting trials

for GC/GEJC

Study to Evaluate the Efficacy and Safety of Camrelizumab and Apatinib in Patients With GC/GEJC NCT04342910Phase 31 site📍 Beijing Jiangsu HengRui Medicine Co., Ltd. · Tests: camrelizumab, Apatinib Mesylate, Paclitaxel, Irinotecan Lenvatinib Plus Tislelizumab and CapeOX as First-Line Treatment for Advanced GC/GEJC With Positive PD-L1 and Low TMEscore NCT06157996Phase 21 site📍 Guangzhou Nanfang Hospital, Southern Medical University · Tests: lenvatinib and tislelizumab plus CapeOX chemotherapy, tislelizumab plus CapeOX chemotherapy A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors NCT07070232Phase 1, Phase 277 sites📍 Phoenix📍 San Francisco📍 Hartford BioNTech SE · Tests: BNT326, Pumitamig, Itraconazole, Paroxetine A Phase II Trial of Perioperative Adebrelimab Combined With XELOX in Resectable Locally Advanced Gastric/Gastroesophageal Junction Cancer (GC/GEJC) NCT06506292Phase 21 site📍 Tianjin Tianjin Medical University Cancer Institute and Hospital · Tests: Adebrelimab, XELOX A Random, Non-controlled, Open Clinical Study of Apatinib Mesylate Combined With Albumin-bound Paclitaxel ± Adebrelimab in Treating Advanced Second-line Gastric Cancer NCT07770113Phase 21 site📍 Zhengzhou The First Affiliated Hospital of Zhengzhou University · Tests: Adebrelimab, Apatinib, Albumin-bound paclitaxel A Study Comparing BL-M05D1 With the Investigator's Choice of Treatment Regimen in Patients With Claudin (CLDN)18.2-Positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma (GC/GEJC) Who Have Received Prior First-Line Treatment NCT07518147Phase 31 site📍 Beijing Sichuan Baili Pharmaceutical Co., Ltd. · Tests: BL-M05D1, Paclitaxel, Docetaxel, Irinotecan hydrochloride XELOX Combined With Sintilimab and HBO for Advanced or Metastatic GC/GEJC NCT06742411Phase 1, Phase 22 sites📍 Chengdu📍 Chengdu West China Hospital · Tests: XELOX+Sintilimab+HBOT Disitamab Vedotin Combined With SOX Regimen Versus SOX Alone as Adjuvant Therapy for HER2-Moderate/High Expressing Stage Ⅲ Gastric Cancer: A Prospective, Multicenter, Randomized, Phase Ⅱ Clinical Trial NCT07474324Phase 21 site📍 Nanjing The First Affiliated Hospital with Nanjing Medical Universi… · Tests: RC48, SOX Chemotherapy, SOX(normal)
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy